Английская Википедия:Applied Genetic Technologies Corporation

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Multiple issues Шаблон:Infobox company

The Applied Genetic Technologies Corporation is a publicly traded (Шаблон:NASDAQ)[1] biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida.[2] In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.[3]

The company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat achromatopsia, X-linked retinoschisis,[4][5] X-linked retinitis pigmentosa,[6] and age-related macular degeneration.[7] The company has six products in various stages of development; as of 2016, none had yet been approved.[8]

In January 2017, AGTC entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. Through the collaboration, AGTC and Bionic Sight will to develop a new optogenetic therapy that leverages AGTC's deep experience in gene therapy and ophthalmology.[9]

On January 9, 2020, the company reported positive results from a Phase 1/2 trial for its investigational gene therapy for retinitis pigmentosa.[10] A few weeks later, the company reported interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs in patients with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes.[11] Applied Genetic Technologies Corporation is a patient partner within the blinding eye disease and rare disease community, including organizations like Foundation for Fighting Blindness and Global Genes.[12]

References

Шаблон:Reflist

External links

Шаблон:Authority control


Шаблон:US-company-stub